Clinical Trial Update: Procalcitonin as a Marker of Bacterial Pneumonia [NA]

View source ↗

Summary

A completed clinical trial evaluating procalcitonin as a biomarker for bacterial pneumonia in patients with pneumonia, bronchitis, or COPD.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchitis
• Chronic Obstructive Pulmonary Disease
• Pneumonia

Snippet

Sponsor: Aarhus University Hospital Skejby | Conditions: Pneumonia, Bronchitis | NA | Status: COMPLETED